Besides, Twist expression was notablely higher in TNBC (87.3%, 55/63), followed by the positive HER2 status (71.8%, 51/71), Luminal B (52.1%, 25/48) and Luminal A types (39.4%, 89/226) in terms of molecular subtypes in breast cancer[29] Therefore, collective observations have demonstrated that Twist over-expression could be an appropriate biomarker in breast cancer prognosis. Here, TWIST1 is linked to breast carcinoma.